following a resubmission considered under the orphan process
co-careldopa (Duodopa®) intestinal gel is not recommended for use within NHS Scotland.
Indication under review: treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
In a phase III, 12-week study, co-careldopa intestinal gel significantly reduced ‘off’ time compared with oral levodopa plus a dopa decarboxylase inhibitor.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
|Drug Name:||co-careldopa (Duodopa)|
|SMC Drug ID:||316/06|
|Indication:||treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.|
|Sub Category:||4.9 Drugs used in Parkinsonism and related disorders|
|Date Advice Published:||7 December 2015|
|co-careldopa intestinal gel, 20mg/5mg levodopa/cabidopa per ml for continuous intestinal infusion (D||Full submission||9 October 2006|